Clinical trials: Placebo Group
Schizophrenia
A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
A study to evaluate the efficacy and safety of an experimental drug (SEP-363856) in acutely psychotic adults with schizophrenia
- Trial name
- NCT02969382
- Testing
- SEP-363856
- Where
- 33 sites in United States, Hungary and 3 more
- Volunteers
- 245 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Asthma
A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo
This purpose of the study is to investigate if budesonide pMDI 160 �g twice a day during 6 weeks is effective and safe in treating asthmatic children aged 6 to <12 years
- Trial name
- CHASE 1 (NCT01136382)
- Testing
- budesonide
- Where
- 87 sites in United States, Bulgaria and 5 more
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Migraine, Migraine With Aura
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- EMERGE (NCT03901482)
- Testing
- Dihydroergotamine
- Where
- 117 sites in United States
- Volunteers
- 1,201 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Major Depressive Disorder
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01435759
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
- Where
- 82 sites in United States, Argentina and 3 more
- Volunteers
- 1,197 people
- Sponsor
- Shire
Diabetes
Phase III Insulin Add-On Asia Regional Program - ST
The purpose is to determine if after 24 weeks of oral daily administration, there will be a greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with Dapagliflozin 10 mg plus insulin compared to…
- Trial name
- NCT02096705
- Testing
- Dapagliflozin
- Where
- 29 sites in China, Singapore and 1 more
- Volunteers
- 477 people
- Sponsor
- AstraZeneca
Lupus Erythematosus, Systemic
A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
This current Phase 3 study will evaluate the efficacy and safety of administration of subcutaneous (sc) IPP-201101 in patients with active SLE.
- Trial name
- LUPUZOR (NCT02504645)
- Testing
- IPP-201101, Standard of Care
- Where
- 30 sites in United States, Czechia and 6 more
- Volunteers
- 202 people
- Sponsor
- ImmuPharma
Coronary Artery Disease
Study of the Vascular Effects of Serelaxin
This was a mechanistic study in patients with coronary artery disease on the effects of Serelaxin on micro- and macrovascular function.
- Trial name
- NCT01979614
- Testing
- Serelaxin
- Where
- 3 sites in United Kingdom
- Volunteers
- 58 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis
The purpose of this study is to determine whether tanezumab is effective in the treatment of pain associated with chronic prostatitis.
- Trial name
- NCT00826514
- Testing
- Tanezumab
- Where
- 44 sites in United States, Canada and 3 more
- Volunteers
- 62 people
- Sponsor
- Pfizer
Healthy
This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 730357 Are Taken up in the Body and How Well They Are Tolerated
The main objective of this trial is to investigate the safety and tolerability of BI 730357 in Japanese healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03793621
- Testing
- BI 730357
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Narcolepsy
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
This trial is a 12-week, randomized, double-blind, placebo controlled, multicenter, 4-treatment parallel group study of the safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with narcolepsy.
- Trial name
- NCT02348593
- Testing
- JZP-110
- Where
- 60 sites in United States, Canada and 4 more
- Volunteers
- 239 people
- Sponsor
- Jazz Pharmaceuticals
Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group 3-arm study to investigate 2 different doses of subcutaneous (SC) IgPro20 compared with placebo for maintenance treatment of…
- Trial name
- NCT01545076
- Testing
- IgPro20 (low dose), IgPro10, IgPro20 (high dose)
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 208 people
- Sponsor
- CSL Behring
Ischemia-Reperfusion Injury, Kidney Diseases
Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8.
- Trial name
- NCT00248040
- Testing
- Reparixin continuous infusion, reparixin intermittent infusion
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Dompé Farmaceutici S.p.A
Asthma
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with asthma.
- Trial name
- NCT00467740
- Testing
- BI 1744 CL
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to pioglitazone with or without metformin, over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-P (NCT00763815)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Pioglitazone
- Where
- 150 sites in United States, Austria and 11 more
- Volunteers
- 484 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease (COPD)
A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to assess the tolerability (effect of drug on body) and pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPD
- Trial name
- NCT00703391
- Testing
- AZD9668
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Menopausal and Female Climacteric States
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
The purpose of this study is to determine whether GSK232802 is safe and effective in reducing the frequency and severity of hot flashes associated with menopause.
- Trial name
- NCT00604825
- Testing
- GSK232802, PREMARIN
- Where
- 87 sites in United States, Argentina and 7 more
- Volunteers
- 356 people
- Sponsor
- GlaxoSmithKline
Bilateral Nasal Polyposis
Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device
The primary objective of this study was to compare the efficacy of intranasal administration of 100, 200, and 400 μg twice daily (bid) of fluticasone propionate, delivered by the Optinose device, with matching placebo in subjects…
- Trial name
- NCT01624662
- Testing
- Fluticasone propionate
- Where
- 10 sites in United States
- Volunteers
- 323 people
- Sponsor
- Optinose US Inc.
Alzheimer's Disease
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD (NCT02670083)
- Testing
- Crenezumab
- Where
- 196 sites in United States, Australia and 28 more
- Volunteers
- 813 people
- Sponsor
- Hoffmann-La Roche
Thrombocytopenia Associated With Chronic Liver Disease
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia
This is a phase 2, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag for Japanese subjects with thrombocytopenia associated with chronic liver disease.
- Trial name
- NCT02227693
- Testing
- avatrombopag
- Where
- 14 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Eisai Co., Ltd.
Rheumatoid Arthritis
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not…
- Trial name
- OSKIRA - 2 (NCT01197534)
- Testing
- fostamatinib
- Where
- 149 sites in United States, Canada and 14 more
- Volunteers
- 913 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.